



G M C A & Co.

Chartered Accountants

Office : 101, "Parishram", 5-B, Rashmi Society, Nr. LG Showroom, Mithakhali Six Road, Navrangpura,
Ahmedabad-380 009. Ph. : 079-40037372, E-mail : gmca1973@gmail.com

Auditor's Report on Standalone Quarterly Financial Results and Year to Date Results of Vivanza Biosciences Ltd. pursuant to Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

Independent Auditors' Review Report

To
The Board of Directors,
Vivanza Biosciences Ltd.


We have reviewed the accompanying statement of Standalone Unaudited Financial results of Vivanza Biosciences Ltd. for the quarter ended 30th September, 2016, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015. This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Accounting Standard for Interim Financial Reporting (AS 25), Prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan & perform the review to obtain moderate assurance as to whether the statement is free of Material Misstatement. A review is limited primarily to Inquires of the Company's personnel & analytical procedures applied to the financial data & thus provide less assurance than audit. We have not performed an Audit & accordingly we do not express an Audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For, G M C A & CO.
Chartered Accountants
FRN: 109850W


CA. Mitt S. Patel
Partner

Membership No: 163940

Place: Ahmedabad
Date: 14th November, 2016

VIVANZA BIOSCIENCES LIMITED

(Formerly Known as IVEE INJECTAA LTD)

Registered Office: 702 "A" wing, Ashoka Chambers, Rasala Marg, Ellisbridge, Ahmedabad 380 006.
CIN : L24110GJ1982PLC005057

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2016.

Part I		(Rs. in Lacs except per share data)					
		Quarter Ended			Six Month Ended		Year Ended
Particulars		30/09/2016	30/06/2016	30/09/2015	30/09/2016	30/09/2015	31/03/2016
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	(a) Net Income from Operations	46.70	0.00	0.00	46.70	0.00	0.00
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income from Operations (net)	46.70	0.00	0.00	46.70	0.00	0.00
2	Expenses						
	(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	38.82	0.00	0.00	38.82	0.00	0.00
	(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	-0.05	0.00	0.00	-0.05	0.00	0.00
	(d) Employee benefits expense	9.96	9.93	0.00	19.89	0.00	0.00
	(e) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00	0.00
	(f) Other expenses	2.07	4.45	0.91	6.52	3.80	6.08
	Total Expenses	50.80	14.38	0.91	65.18	3.80	6.08
	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	-4.10	-14.38	-0.91	-18.48	-3.80	-6.08
4	Other Income	0	0	0.00	0	0.00	0.05
	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3-4)	-4.10	-14.38	-0.91	-18.48	-3.80	-6.03
6	Finance Costs	0.00	0.00	0.00	0.00	0.00	0.00
	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	-4.10	-14.38	-0.91	-18.48	-3.80	-6.03
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7-8)	-4.10	-14.38	-0.91	-18.48	-3.80	-6.03
10	Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00
11	Net Profit / (Loss) from ordinary after tax (9-10)	-4.10	-14.38	-0.91	-18.48	-3.80	-6.03
12	Extraordinary items (net of tax expenses)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11-12)	-4.10	-14.38	-0.91	-18.48	-3.80	-6.03
14	Share of Profit / (Loss) of associates *	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority Interest *	0.00	0.00	0.00	0.00	0.00	0.00
16	Net Profit / (Loss) after taxes , minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	-4.10	-14.38	-0.91	-18.48	-3.80	-6.03
17	Paid-up equity share capital (Face value of ` 10/- each)	255.00	255.00	18.80	255.00	18.80	18.80
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	(34.79)	(14.08)	(16.31)
19.i	Earnings Per Share (before extraordinary items) (not annualised):						
	(a) Basic	-0.16	-0.56	-0.48	-0.72	-2.02	-3.21
	(b) Diluted	-0.16	-0.56	-0.48	-0.72	-2.02	-3.21
19.ii	Earnings Per Share (after extraordinary items) (not annualised):						
	(a) Basic	-0.16	-0.56	-0.48	-0.72	-2.02	-3.21
	(b) Diluted	-0.16	-0.56	-0.48	-0.72	-2.02	-3.21


Notes:

- The above standalone unaudited financial results were reviewed by the statutory Auditors, recommended by the Audit Committee and taken on record by the Board of Directors at their meeting held on Monday 14 November, 2016.
- Company operates only in single segment i.e. pharmaceuticals related activities
- The Statutory Auditors have carried out a limited review of the financial results for the quarter ending September 30, 2016.
- The previous quarter's/year's figures have been regrouped/rearranged wherever necessary to make it comparable with the current quarter/year.


Date : 14/11/2016
Place : Ahmedabad

For, VIVANZA BIOSCIENCES LIMITED

H. K. K. K.
ADIRECTOR



STATEMENT OF ASSETS AND LIABILITIES		
		(Rs.in Lacs)
Particulars	As at 30/09/2016	As at 31/03/2016
A	EQUITY AND LIABILITIES	
1	Shareholders' Funds	
	(a) Share Capital	255.00
	(b) Reserves and Surplus	(34.79)
	Sub-total - Shareholders' Funds	220.21
2	Non-current Liabilities	
	(a) Long-term borrowings	-
	(b) Deferred Tax Liabilities (Net)	-
	(c) Other Long Term Liabilities	-
	Sub-total - Non-current liabilities	-
3	Current Liabilities	
	(a) Short -term borrowings	116.35
	(b) Trade Payables	21.66
	(c) Other Current Liabilities	8.42
	(d) Short-term Provisions	-
	Sub-total - Current Liabilities	146.44
	TOTAL - EQUITY AND LIABILITIES	366.65
B	ASSETS	
1	Non-current Assets	
	(a) Fixed Assets	-
	(b) Non-current Investments	191.45
	(c) Long-term loans and advances	59.33
	Sub-total - Non-current Assets	250.78
2	Current Assets	
	(a) Inventories	0.05
	(b) Trade Receivables	27.17
	(c) Short -term loans and advances	83.27
	(d) Cash and Cash Equivalents	4.35
	(e) Other current assets	1.03
	Sub-total - Current Assets	115.87
	TOTAL - ASSETS	366.65





GMCA & Co.

Chartered Accountants

Office : 101, "Parishram", 5-B, Rashmi Society, Nr. LG Showroom, Mithakhali Six Road, Navrangpura,
Ahmedabad-380 009. Ph. : 079-40037372, E-mail : gmca1973@gmail.com

Independent Auditors' Review Report

To
The Board of Directors,
Vivanza Biosciences Limited

We have reviewed the accompanying statement of Consolidated Unaudited Financial results of Vivanza Biosciences Limited (The Holding Company) and its Subsidiary Company (The Holding Company and its Subsidiary Collectively referred to as "The Group") for the quarter ended 30th September, 2016, attached herewith, being submitted by the Holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015. This statement which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Accounting Standard for Interim Financial Reporting (AS 25), Prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of the Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan & perform the review to obtain moderate assurance as to whether the statement is free of Material Misstatement. A review is limited primarily to Inquires of the Holding Company's personnel & analytical procedures applied to the financial data & thus provide less assurance than audit. We have not performed an Audit & accordingly we do not express an Audit opinion.

The statement includes the results of the wholly-owned subsidiary, Vivanza Life Sciences Private Limited (The Subsidiary Company)

We did not review the Interim Financial Results of the Subsidiary whose Interim Financial Information reflects NIL Revenue & Rs. 5,54,415/- Net Loss after tax for the Quarter ended 30th September, 2016. This interim financial information of the subsidiary have not been audited by the any Auditors rather they have been signed & declared by the Directors of the Company & our report on the statement, in so far as it relates to the amounts and disclosures included in respect of the Subsidiary, is based solely on the Financial Statements signed & declared by the Board of Directors of the Subsidiary Company.

Based on our review conducted as above, and based on consideration of the signed & declared Financial Statements referred in the above paragraph, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting




practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, G M C A & CO.
Chartered Accountants
FRN: 109850W



Place: Ahmedabad
Date: 14th November, 2016


CA. Mitt S. Patel
Partner
Membership No: 163940

VIVANZA BIOSCIENCES LIMITED

(Formerly Known as IVEE INJECTAA LTD)

Registered Office: 702 "A" wing, Ashoka Chambers, Rasala Marg, Ellisbridge, Ahmedabad 380 006.

CIN : L24110GJ1982PLC005057


STATEMENT OF CONSOLIDATE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2016.

Part I		(Rs. in Lacs except per share data)		
		Quarter Ended		Six Month Ended
Particulars		30/09/2016	30/06/2016	30/09/2016
		Unaudited	Unaudited	Unaudited
1	Income from Operations			
	(a) Net Income from Operations	46.70	0.00	46.70
	(b) Other Operating Income	0.00	0.00	0.00
	Total Income from Operations (net)	46.70	0.00	46.70
2	Expenses			
	(a) Cost of Materials consumed	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	38.82	0.00	38.82
	(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	-0.05	0.00	-0.05
	(d) Employee benefits expense	15.08	9.93	25.01
	(e) Depreciation and amortisation expense	0.00	0.00	0.00
	(f) Other expenses	2.48	4.45	6.93
	Total Expenses	56.33	14.38	70.71
	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	-9.63	-14.38	-24.01
3	Other Income	0	0	0
	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3-4)	-9.63	-14.38	-24.01
5	Finance Costs	0.01	0.00	0.01
	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	-9.64	-14.38	-24.02
7	Exceptional Items	0.00	0.00	0.00
	Profit / (Loss) from ordinary activities before tax (7-8)	-9.64	-14.38	-24.02
9	Tax Expense	0.00	0.00	0.00
	Net Profit / (Loss) from ordinary after tax (9-10)	-9.64	-14.38	-24.02
12	Extraordinary items (net of tax expenses)	0.00	0.00	0.00
	Net Profit / (Loss) for the period (11-12)	-9.64	-14.38	-24.02
14	Share of Profit / (Loss) of associates *	0.00	0.00	0.00
15	Minority Interest *	0.00	0.00	0.00
	Net Profit / (Loss) after taxes , minority interest and share of profit / (loss) of associates (13 + 14 + 15)*	-9.64	-14.38	-24.02
17	Paid-up equity share capital (Face value of ` 10/- each)	255.00	255.00	255.00
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-
19.i	Earnings Per Share (before extraordinary items) (not annualised):			
	(a) Basic	-0.38	-0.56	-0.94
	(b) Diluted	-0.38	-0.56	-0.94
19.ii	Earnings Per Share (after extraordinary items) (not annualised):			
	(a) Basic	-0.38	-0.56	-0.94
	(b) Diluted	-0.38	-0.56	-0.94

Notes:

- The above consolidate unaudited financial results were reviewed by the statutory Auditors, recommended by the Audit Committee and taken on record by the Board of Directors at their meeting held on Monday 14 November, 2016.
- Company operates only in single segment i.e. pharmaceuticals related activities
- The Statutory Auditors have carried out a limited review of the financial results for the quarter ending September 30, 2016.
- Vivanza Lifesciences Private Limited (formerly Fortune Beverages Private Limited) (VLPL) became Wholly Owned Subsidiary of the Company w.e.f. June 17, 2016. Hence, figures for corresponding quarter ended and year to date figures for the previous year and figures for the previous year ended are not available and provided for.

Date : 14/11/2016
Place : Ahmedabad

For, VIVANZA BIOSCIENCES LIMITED
Ahmedabad

DIRECTOR

STATEMENT OF ASSETS AND LIABILITIES		(Rs.in Lacs)
Particulars		As at 30/09/2016
A	EQUITY AND LIABILITIES	
1	Shareholders' Funds	
	(a) Share Capital	255.00
	(b) Reserves and Surplus	(109.68)
	Sub-total - Shareholders' Funds	145.32
2	Non-current Liabilities	
	(a) Long-term borrowings	-
	(b) Deferred Tax Liabilities (Net)	-
	(c) Other Long - term Liabilities	-
	(d) Long - term Provisions	-
	Sub-total - Non-current liabilities	-
3	Current Liabilities	
	(a) Short - term borrowings	191.66
	(b) Trade Payables	21.66
	(c) Other Current Liabilities	9.56
	(d) Short-term Provisions	-
	Sub-total - Current Liabilities	222.88
	TOTAL - EQUITY AND LIABILITIES	368.20
B	ASSETS	
1	Non-current Assets	
	(a) Fixed Assets	72.83
	(b) Non-current investments	91.45
	(c) Long-term loans and advances	59.33
	(d) Other Non-current assets	-
	Sub-total - Non-current Assets	223.61
2	Current Assets	
	(b) Inventories	0.05
	(c) Trade Receivables	27.17
	(d) Cash and Cash Equivalents	10.36
	(e) Short-term loans and advances	105.99
	(d) Other current assets	1.03
	Sub-total - Current Assets	144.59
	TOTAL - ASSETS	368.20

